Standout Papers

Outcomes in refractory diffuse large B-cell lymphom... 2009 2026 2014 2020 994
  1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study (2017)
    Michael Crump, Sattva S. Neelapu et al. Blood
  2. Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (2009)
    Georg Heß, Raoul Herbrecht et al. Journal of Clinical Oncology
  3. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study (2011)
    Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology

Immediate Impact

10 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
T-cell-engaging bispecific antibodies in cancer
2023 Standout

Works of Michael Crump being referenced

CD20‐TCB (RG6026), A NOVEL “2:1” FORMAT T‐CELL‐ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN'S LYMPHOMA
2019
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout

Author Peers

Author Last Decade Papers Cites
Michael Crump 5429 5150 2308 300 9.5k
Jorge Romaguera 7051 5289 3220 280 9.7k
Ann S. LaCasce 4800 3336 2230 204 7.4k
Jonathan W. Friedberg 8916 6334 3744 392 12.3k
André Bosly 5711 4721 2343 190 9.5k
Franco Cavalli 7560 4911 2594 187 11.3k
Peter Mauch 5035 3628 1738 241 10.7k
Nicolas Mounier 5901 4393 1938 204 8.0k
Massimo Federico 7852 5384 2000 281 11.7k
Catherine Thiéblemont 9600 6772 4215 406 13.8k
Won Seog Kim 6850 6075 1722 454 10.4k

All Works

Loading papers...

Rankless by CCL
2026